PRLD Stock News & Catalysts – Prelude Therapeutics

FEATURED

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the

Summary

Oct 16, 2026, 4:01 PM ·Globe Newswire

RECENT

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026 The collaboration is underpinned by

Oct 13, 2026, 7:01 AM ·Globe Newswire

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the

Sep 11, 2026, 7:01 AM ·Globe Newswire

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company

Sep 10, 2026, 7:01 AM ·Globe Newswire

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated

Aug 11, 2026, 7:00 AM ·Globe Newswire

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class

May 12, 2026, 7:01 AM ·Globe Newswire

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the pricing of its

Apr 20, 2026, 6:30 AM ·Globe Newswire

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File

Apr 20, 2026, 6:00 AM ·Globe Newswire

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today announced that Dr.

Apr 15, 2026, 7:30 AM ·Globe Newswire

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company's oral KAT6A

Mar 17, 2026, 4:31 PM ·Globe Newswire

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and

Mar 10, 2026, 7:01 AM ·Globe Newswire

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and

Feb 5, 2026, 9:26 AM ·Globe Newswire

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to

Feb 3, 2026, 9:00 AM ·Globe Newswire

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster

Dec 16, 2025, 12:18 PM ·Globe Newswire

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in

Dec 6, 2025, 11:00 AM ·Globe Newswire

Prelude Therapeutics Incorporated PRLD · News